Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 13, 2026BMC PediatricsOpen Access

Comparing the impact of blinatumomab therapy versus standard chemotherapy on the progression of relapsed/refractory pediatric B-ALL: a two-center retrospective cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

AEAziz EghbaliZNZeynab Nasri NasrabadiMFMohammad Faranoush

Discussion

Loading...

Member takes

Overview

Cohort study shows blinatumomab enhances complete remission in pediatric B-ALL, indicating it as a preferred treatment option.

Key Points

  • This research aims to compare the effectiveness of blinatumomab and standard chemotherapy in pediatric relapsed/refractory B-ALL patients.
  • Conducted a two-center retrospective cohort study
  • Included pediatric patients aged 1–18 diagnosed with relapsed/refractory CD19⁺ B-ALL
  • Compared outcomes after administration of blinatumomab versus conventional chemotherapy
  • Blinatumomab group had significantly higher MRD negativity rates (83.4% vs. 18.2%)
  • Higher percentage of patients in the blinatumomab group proceeded to allo-HSCT (68.2% vs. 40%)
  • Overall survival improved significantly with blinatumomab (77.3% vs. 30%)

Cite This Study

Eghbali et al. (2026) studied this question.

synapsesocial.com/papers/6a03cc1b1c527af8f1ecfedchttps://doi.org/10.1186/s12887-026-06942-z
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Blinatumomab vs. chemotherapy in pediatrics B-cell ALL: A meta-analysis of randomized controlled trials2025
  2. 2Bispecific monoclonal antibody blinatumomab in the first-line therapy of B-lineage acute lymphoblastic leukemia in children and adolescents: interim results of the Russian Ministry of Health approbation protocol2024
  3. 3Blinatumomab demonstrates MRD eradication in MRD-positive/chemotherapy-delayed pediatric B-ALL and high response in relapsed/refractory cases: a multicenter cohort study2025
  4. 4Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia2026 · 1 citations
  5. 5Blinatumomab for Pediatric High-Risk B-Cell Precursor Acute Lymphoblastic Leukemia: Safety, MRD Response and Survival in a Single-Center Retrospective Cohort2026